Handelsavisen
prelaunch
Companies Healthcare HLYK.PK
HL
HLYK.PK OTC Healthcare Providers & Services

Hlyk.Pk

$2,95
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
Op margin
-86,9 %
ROE
56,9 %
Net margin
-158,8 %
Debt / equity
-0,15
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
2026-10-28
Ex-dividend
TR 1Y
About

HLYK.PK operates in the healthcare facilities and services industry, focusing on biotechnology, and generates revenue primarily through its healthcare services and equipment offerings.

Business. HLYK.PK operates in the healthcare facilities and services industry, focusing on biotechnology, and generates revenue primarily through its healthcare services and equipment offerings.

Classification99 %
SectorHealth Care
Industry groupHealthcare Providers & Services
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
  • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
56,9 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning HLYK.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to HLYK.PK. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Company
    • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    HLYK.PK operates in the healthcare facilities and services industry, focusing on biotechnology, and generates revenue primarily through its healthcare services and equipment offerings.

    Classification99 %
    SectorHealth Care
    Industry groupHealthcare Providers & Services
    AI synthesis
    GENERATED

    HLYK.PK exhibits a highly leveraged capital structure, with total liabilities of $7.46 million and total equity of -$5.76 million, resulting in a negative debt-to-equity ratio of -0.15. The company's liquidity position is weak, as evidenced by a current ratio of 0.22, indicating that it has insufficient current assets to cover its current liabilities. The operating cash flow of -$1.71 million and free cash flow of -$3.18 million further underscore the company's cash flow challenges.

    Profitability metrics for HLYK.PK are concerning, with a net loss of $3.28 million and an operating loss of $1.79 million. The return on equity of 56.93% is misleading due to the negative equity base, and the return on assets of -1.93% indicates that the company is not generating returns on its asset base. These figures fall significantly below the industry median for profitability and returns, suggesting a poor performance relative to its peers.

    The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases the risk associated with the company's revenue streams, as it is highly dependent on a single source of income.

    HLYK.PK's growth trajectory is negative, with a net loss and declining cash flows indicating a lack of growth momentum. The company's financial performance suggests that it is not on a path to sustainable growth, and without significant operational improvements or external financing, it may struggle to maintain its operations.

    The risk assessment for HLYK.PK highlights a medium liquidity risk and a low dilution risk. The company's negative net cash position after subtracting total debt is a key flag, indicating that it may need to raise additional capital to meet its obligations. The low dilution risk suggests that the company is not currently planning significant equity issuances, but the need for capital could change this outlook.

    Recent events and filings for HLYK.PK have not been disclosed in the available data, so no specific recent developments can be reported. However, the company's financial position suggests that it may be under pressure to secure additional financing or restructure its operations to address its liquidity and profitability issues.

    Key takeaways
    • HLYK.PK has a highly leveraged capital structure with a negative equity position.
    • The company is experiencing significant operating and net losses, indicating poor profitability.
    • Revenue is concentrated in a single segment, increasing business risk.
    • The company's liquidity position is weak, with a current ratio of 0.22.
    • HLYK.PK is not on a positive growth trajectory and may require external financing to continue operations.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $2,95
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    -$5.8M
    Net cash
    -$839.6k
    Current ratio
    0.2
    Debt / equity
    -0.1
    ROA
    -1.9%
    ROE
    56.9%
    Cash conversion
    52.0%
    CapEx / revenue
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    INDUSTRYSEGMENTCOMPANYHealthcareIndustryHealthcare Providers & Services16,0B node revenueOPCH 35,3%PACS 33,0%PRVA 13,3%SHC 7,3%NUTX 5,5%TOI 3,1%VMD 1,7%JYNT 0,3%Other 0,5%
    Source: company disclosures · own-taxonomy revenue-covered setHLYK 0,0% · rank #15 of 16

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    Peer comparison8 peers · vs HLYK · multiples and returns
    OP
    OPCH
    Option Care Health Inc
    $22,09
    3,5B USD
    P/E
    16,5x
    vs self
    Div yield
    vs self
    ROE
    15,5 %
    vs self
    PA
    PACS
    Pacs Group Inc
    $38,00
    6,0B USD
    P/E
    25,2x
    vs self
    Div yield
    vs self
    ROE
    25,8 %
    vs self
    PR
    PRVA
    Privia Health Group Inc
    $23,90
    3,0B USD
    P/E
    123,6x
    vs self
    Div yield
    vs self
    ROE
    3,1 %
    vs self
    SH
    SHC
    Sotera Health Co
    $18,00
    5,1B USD
    P/E
    57,5x
    vs self
    Div yield
    vs self
    ROE
    12,9 %
    vs self
    NU
    NUTX
    NUTEX HEALTH INC.
    $176,00
    1,2B USD
    P/E
    9,7x
    vs self
    Div yield
    vs self
    ROE
    29,2 %
    vs self
    TO
    TOI
    Oncology Institute Inc
    $5,18
    527,8M USD
    P/E
    vs self
    Div yield
    vs self
    ROE
    372,2 %
    vs self
    VM
    VMD
    Viemed Healthcare Inc
    $11,00
    445,4M USD
    P/E
    26,7x
    vs self
    Div yield
    vs self
    ROE
    10,4 %
    vs self
    JY
    JYNT
    Joint Corp
    $8,21
    117,0M USD
    P/E
    vs self
    Div yield
    vs self
    ROE
    -15,5 %
    vs self

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin-86,9 %Bottom quartile
    Net Margin-158,8 %Bottom quartile
    ROE56,9 %Best in class
    D/E-0,15Above P75
    Cash Conv0,52Below median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    • Return On Assets
      net_income / total_assets
    Source documents
    • HLYK.PK Market data — financials · 2026-05-28

    Ownership & reference

    Leadership

    • Michael T DentChairman of the Board, Chief Executive Officer

    Insider activity

    — missing data

    Short positioning

    274shares short+45.0% vs prior
    1days to cover
    1.1Kfails-to-deliver
    as of 2026-06-30 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    HLYK.PKCanonical
    OTC · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    • Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 51.0%Derived (calculated)
    • Total assets (YoY) (2025-12-31 vs 2024-12-31): -23.4%Derived (calculated)
    • Operating income (YoY) (2025-12-31 vs 2024-12-31): 54.8%Derived (calculated)
    • Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -84.1%Derived (calculated)
    • Return on equity (FY 2025-12-31): 56.9%Derived (calculated)
    • Return on assets (FY 2025-12-31): -192.7%Derived (calculated)
    • Current ratio (FY 2025-12-31): 0.22xDerived (calculated)
    • Debt-to-equity (FY 2025-12-31): -1.30xDerived (calculated)
    • Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 39.5%Derived (calculated)
    • Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): -51.3%Derived (calculated)
    • EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 46.8%Derived (calculated)
    • EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 46.8%Derived (calculated)
    • Net income (YoY) (2025-12-31 vs 2024-12-31): 46.5%Derived (calculated)
    • Total assets (annual): USD 1.7MSEC XBRL filing
    • Total liabilities (annual): USD 7.46MSEC XBRL filing
    • EPS (diluted) (annual): USD-PER-SHARES -1SEC XBRL filing
    • Cash & equivalents (annual): USD 37.14KSEC XBRL filing
    • Operating income (annual): USD -2.11MSEC XBRL filing
    • Net income (annual): USD -3.28MSEC XBRL filing
    • Total operating expenses (annual): USD 4.18MSEC XBRL filing
    • EPS (basic) (annual): USD-PER-SHARES -1SEC XBRL filing
    • Shareholders' equity (annual): USD -5.76MSEC XBRL filing
    • Current assets (annual): USD 1.55MSEC XBRL filing
    • Current liabilities (annual): USD 7.01MSEC XBRL filing
    Showing 24 of 60 surfaced claims.
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage